CN Patent

CN105111119B — 一类卤代苯l‑薄荷醇类p2y12受体拮抗剂及其用途

Assigned to Chengdu Croma Biotechnology Co ltd · Expires 2017-04-12 · 9y expired

What this patent protects

本发明涉及与心血管疾病相关的药物领域。具体而言，本发明涉及一类含卤代苯和L‑薄荷醇结构的P2Y12受体拮抗剂、其制备方法以及在制备治疗心血管疾病尤其是血栓栓塞性疾病药物中的应用。 其中，X选自卤素取代基。

USPTO Abstract

本发明涉及与心血管疾病相关的药物领域。具体而言，本发明涉及一类含卤代苯和L‑薄荷醇结构的P2Y12受体拮抗剂、其制备方法以及在制备治疗心血管疾病尤其是血栓栓塞性疾病药物中的应用。 其中，X选自卤素取代基。

Drugs covered by this patent

Patent Metadata

Patent number
CN105111119B
Jurisdiction
CN
Classification
—
Expires
2017-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Croma Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.